Loading...
Esomeprazole is the S-isomer of omeprazole. Results of pharmacokinetic and pharmacodynamic studies have demonstrated higher systemic bioavailability for esomeprazole compared with omeprazole because of less first-pass hepatic metabolism and lower plasma clearance. Researchers conducted this double-blind, multicenter study to examine the potential clinical implications of esomeprazole in the treatment of patients with gastroesophageal reflux disease (GERD). They randomized 1960 patients with erosive esophagitis to receive oral dosages of esomeprazole (40 mg or 20 mg) or omeprazole (20 mg) daily for 8 weeks.
The primary efficacy variable was the proportion of patients with healed erosive esophagitis at 8 weeks. Secondary variables were heartbu…